Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Withdrawn before enrolling · Phase 2
Conditions studied: Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Biological therapies such as interferon alfa-2b use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of rituximab or interferon alfa-2b in treating patients who have chronic lymphocytic leukemia or multiple myeloma in remission.
Key facts
- Study ID
- NCT00004040
- Run by
- Hoag Memorial Hospital Presbyterian
- People needed
- 0
- Starts
- 1998-06-01
- Expected to finish
- 1999-06-01
- Last updated by the study team
- 2015-08-19
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
- Baptist Regional Cancer Center - Knoxville — Knoxville, Tennessee, United States
- St. Joseph Regional Cancer Center — Bryan, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.